TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29671368
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) + vitamin E
Study: 29671368
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) + vitamin C
Study: 29671368
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) alone
Study: 24521245
Drug: Lixisenatide (LIXI)
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lixisenatide (LIXI) 20 µg
Study: 22468806
Drug: Pemetrexed 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 1,800 mg/m2 plus cyclophosphamide 600 mg/m2
Study: 22468806
Drug: Pemetrexed 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 600 mg/m2 plus cyclophosphamide 600 mg/m2
Study: 15655124
Drug: Lisinopril with
Normalized name: LISINOPRIL 20 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET [Lisinopril with Hydrochlorothiazide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril with or without hydrochlorothiazide, or nifedipine or an angiotensin receptor blocker for uncontrolled hypertensive subjects
Study: 15655124
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no treatment) for normotensive and treated hypertensive subjects
Study: 7796586
Drug: Oral monophasic
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral monophasic contraceptive (ethinylestradiol 20 micrograms + desogestrel 0.150 mg)
Study: 2356085
Drug: Prophylactic diflunisal
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic diflunisal (two tablets immediately at the conclusion of the visit, then four tablets to be taken in the schedule of one every 8 to 12 hours for pain if needed)
Study: 2356085
Drug: On-demand diflunisal
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-demand diflunisal (same dosage schedule; pills to be taken only if needed)
Study: 26689281
Drug: Pre-quit nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-quit nicotine patch treatment (two weeks of patch treatment prior to a quit day, followed by 10 weeks post-quit treatment)
Study: 26689281
Drug: Standard patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard patch treatment (10 weeks of patch starting from a designated quit day)
Study: 21380937
Drug: Naltrexone (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (4.5 mg daily)
Study: 15059710
Drug: DHA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (400 mg/d)
Study: 17142642
Drug: Aquatic physical
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic physical therapy for 6 weeks
Study: 17142642
Drug: No aquatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aquatic physical therapy (control)
Study: 11026748
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Ginkgo biloba
Study: 11026748
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg Ginkgo biloba
Study: 11026748
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg Ginkgo biloba
Study: 9062542
Drug: Low-dose beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose beta-carotene (0.5 mg/d) for days 1-60
Study: 3000176
Drug: Sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbinil (250 mg daily for 6 weeks)
Study: 22327755
Drug: Standard hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hospital treatment (n=21)
Study: 20189552
Drug: Informative adjective-noun
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informative adjective-noun phrases (e.g. blue car)
Study: 15653967
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) exposure
Study: 8953203
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment (sulfonylurea)
Study: 1672588
Drug: Intermittent medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent medication (given only when the patient shows early signs of relapse)
Study: 1672588
Drug: Moderate doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate doses of maintenance medication
Study: 1672588
Drug: Intermittent medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent medication
Study: 31281931
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics used prior to culture within 30 days
Study: 25651842
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy (ART) initiation
Study: 22908169
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg piperacillin
Study: 22908169
Drug: 3,000 mg
Normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000 mg piperacillin
Study: 22908169
Drug: High-dose short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose short-term infusions (6 g every 8 h)
Study: 22908169
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous infusions (6 g/day)
Study: 19126633
Drug: Immediate intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate intervention (start of cancer treatment)
Study: 19126633
Drug: Delayed intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed intervention (8 weeks after starting treatment)
Study: 17407391
Drug: Subcutaneous glatiramer
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous glatiramer acetate (SC GA)
Study: 17407391
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a (IM IFNbeta‐1a)
Study: 17407391
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta-1a (SC IFNbeta‐1a)
Study: 17407391
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta-1b (SC IFNbeta‐1b)
Study: 15357164
Drug: Povidone-iodine ointment
Normalized name: Povidone-Iodine Ointment
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine ointment and gauze dressings
Study: 11167352
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg cetirizine
Study: 11167352
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg levocetirizine
Study: 11167352
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ucb 28557
Study: 7833105
Drug: CEV (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEV (cyclophosphamide 1000 mg/m2 i.v., epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks)
Study: 7833105
Drug: PE (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks)
Study: 28051270
Drug: Retroperitoneal laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroperitoneal laparoscopic partial dissection of adipose renal capsule plus ligation of renal pedicle lymphatic vessels (Group A)
Study: 28051270
Drug: Retroperitoneal laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroperitoneal laparoscopic complete dissection of adipose renal capsule plus ligation of renal pedicle lymphatic vessels (Group B)
Study: 26149996
Drug: Lopinavir (LPV)
Normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir (LPV) treatment during pregnancy
Study: 21348538
Drug: Saxagliptin 10
Normalized name: Dapagliflozin/Saxagliptin 10 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 10 mg (Onglyza™)
Study: 21348538
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg (2.5 mg orally once daily)
Study: 16950285
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of farm exposure and CD14-159TT genotype
Study: 7827905
Drug: Preoperative mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative mechanical bowel preparation (group 1)
Study: 7827905
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (group 2)
Study: 3168339
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium chloride (10 mmol in 100 ml isotonic sodium chloride)
Study: 29026903
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g freeze dried blueberry powder (WBB)
Study: 22088858
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day ezetimibe/simvastatin combination therapy
Study: 16355341
Drug: Atazanavir, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir, 400 mg once daily plus efavirenz placebo
Study: 16355341
Drug: Efavirenz, 600
Normalized name: Efavirenz, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz, 600 mg once daily plus atazanavir placebo
Study: 10739509
Drug: Continuous-combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous-combined hormone replacement therapy (conjugated equine estrogens 0.625 mg/d with medroxyprogesterone acetate 2.5 mg/d)
Study: 31001264
Drug: SjCTPI bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SjCTPI bovine vaccine (prime-boost regimen)
Study: 31001264
Drug: Human mass
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human mass chemotherapy (praziquantel)
Study: 31001264
Drug: SjCTPI bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SjCTPI bovine vaccine
Study: 25538277
Drug: H3N2c cell‐culture‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3N2c cell‐culture‐derived vaccine with MF59 adjuvant
Study: 25538277
Drug: H3N2c cell‐culture‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3N2c cell‐culture‐derived vaccine without MF59 adjuvant
Study: 25538277
Drug: 7.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 µg + 0.25 mL MF59
Study: 25538277
Drug: MF59‐adjuvanted H3N2c
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59‐adjuvanted H3N2c vaccines
Study: 22111718
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose budesonide (0.5 mg nightly)
Study: 22111718
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose budesonide (1 mg twice daily for 7 days during respiratory illness)
Study: 18953855
Drug: Partial neuromuscular
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial neuromuscular relaxation maintained at train of four stimulation (TOF)=3 by continuous vencronium infusion
Study: 16409339
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg morphine
Study: 22912697
Drug: Chloroquine monotherapy
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine monotherapy
Study: 1515386
Drug: 17.5 ml
Normalized name: 17.5 ML Fusilev 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 ml mepivacaine
Study: 1515386
Drug: 17.5 ml
Normalized name: 17.5 ML Fusilev 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 ml bupivacaine
Study: 30498351
Drug: 3-monthly paliperidone
Normalized name: paliperidone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-monthly paliperidone palmitate (PP3M)
Study: 30498351
Drug: once-monthly paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: once-monthly paliperidone palmitate (PP1M)
Study: 26845640
Drug: Multifaceted peer-group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted peer-group based intervention including FP communication skills training, antibiotic prescribing agreements, and quarterly feedback figures.
Study: 22152974
Drug: Intensified N-terminal
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified N-terminal brain natriuretic peptide-guided HF therapy
Study: 3302110
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg/day
Study: 3302110
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg/day
Study: 17453362
Drug: Dose-escalated chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated chemotherapy (de FEC)
Study: 15610835
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 microg/kg and thiopental 3 mg/kg (Group 1, men)
Study: 15610835
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 microg/kg and thiopental 3 mg/kg (Group 2, women)
Study: 15610835
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 microg/kg and thiopental 2 mg/kg (Group 3, women)
Study: 9701719
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 50 microgram TRH administered intravenously at 22.00, 23.00, 24.00, and 01.00 h
Study: 31585343
Drug: 10-week internet-delivered
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-week internet-delivered exposure therapy
Study: 25441960
Drug: Tablet computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer usage
Study: 23550808
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dehydroepiandrosterone (DHEA) added to EE/DRSP COC
Study: 12600797
Drug: ibuprofen 400mg
Normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 400mg
Study: 10929920
Drug: Zafirlukast 10
Normalized name: zafirlukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 10 mg BID
Study: 10929920
Drug: Zafirlukast 5
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast 5 mg BID
Study: 11101185
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg BID
Study: 10929920
Drug: Zafirlukast 40
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast 40 mg BID
Study: 8644030
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (nifedipine, verapamil, diltiazem)
Study: 25899875
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment efficacy
Study: 8644030
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists treatment
Study: 3901672
Drug: mianserin 30
Normalized name: mianserin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 30 mg
Study: 3901672
Drug: clonidine 0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: clonidine 0.150 mg
Study: 30836809
Drug: Low-frequency airborne
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency airborne ultrasound therapy (Glybetac)
Study: 18835735
Drug: Oral 17beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17beta‐oestradiol valerate 2mg twice daily
Study: 14745340
Drug: Comparer antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparer antibiotics (amoxicillin-clavulanic acid, amoxicillin, ceftriaxone, ceftriaxone plus cefuroxime +/- erythromycin)
Study: 14745340
Drug: Comparer antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparer antibiotics
Study: 9696721
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g/day)
Study: 9696721
Drug: glycine (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycine (13 g/day; placebo)
Study: 16229022
Drug: Qigong treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong treatment group (n = 32)
Study: 15526246
Drug: Amiodarone 400
Normalized name: amiodarone 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 400 mg daily plus irbesartan 300 mg daily
Study: 15526246
Drug: Amiodarone 400
Normalized name: amiodarone 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 400 mg daily plus irbesartan 150 mg daily
Study: 15526246
Drug: Amiodarone 400
Normalized name: amiodarone 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 400 mg daily
Study: 11139948
Drug: Pilsicainide (PLS)
Normalized name: ethanol
DrugBank: Pilsicainide (DB12712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilsicainide (PLS) 100-150 mg single oral dose
Study: 11139948
Drug: Disopyramide (DISO)
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide (DISO) 2 mg/kg infusion (maximum dose = 100 mg)
Study: 9313630
Drug: Sulodexide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (administered IM for ten days and orally for fifty days)
Study: 9313630
Drug: Calcium Heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Heparin (subcutaneous for sixty days)
Study: 7039840
Drug: Cinoxacin 250
Normalized name: cinoxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinoxacin 250 mg, four times a day
Study: 7039840
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg, four times a day
Study: 30781485
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g of flavanol‐rich cocoa powder ingested with a diabetic‐suitable breakfast
Study: 26174294
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at an estimated brain concentration of 0.90 μg ml(‐1)
Study: 24450487
Drug: Extended combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended combined oral contraceptives
Study: 19443528
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (SFC)
Study: 12644803
Drug: D‐DBA technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐DBA technique (DBA applied immediately after preparations)
Study: 12644803
Drug: No DBA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No DBA technique (no bonding agent used)
Study: 7570509
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (3-4 times a week for 6 weeks, 20-30 minutes per session)
Study: 7570509
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard rehabilitation therapy)
Study: 1937998
Drug: Dilevalol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 600 mg
Study: 6130532
Drug: Atropine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.4 or 0.8 mg subcutaneous injections)
Study: 6130532
Drug: Bethanechol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (2.5 mg)
Study: 6130532
Drug: 16,16-dimethyl prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16,16-dimethyl prostaglandin E2 (DmPGE2, 7 to 140 ng/kg intravenous over five minutes)
Study: 26961929
Drug: DHA plus
Normalized name: PNV-DHA Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA plus EPA (2 g/d)
Study: 29023535
Drug: Carbohydrate‐electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte solution (CES, 6% carbohydrate)
Study: 29023535
Drug: Carbohydrate‐electrolyte‐protein solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte‐protein solution (CEPS, 2% protein plus 4% carbohydrate)
Study: 29023535
Drug: Carbohydrate‐electrolyte‐protein solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte‐protein solution (CEPS)
Study: 12960117
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg EGCG once/day
Study: 12960117
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg EGCG twice/day
Study: 12960117
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg EGCG as Polyphenon E once/day
Study: 12960117
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg EGCG as Polyphenon E twice/day
Study: 15324531
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg three times daily
Study: 1394826
Drug: M-VAC therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-VAC therapy (methotrexate, vinblastine, adriamycin, and cisplatin)
Study: 1394826
Drug: M-VAC therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-VAC therapy